Boston Scientific Corporation has announced a definitive agreement to acquire Penumbra, Inc. for approximately $14.5 billion, marking one of its largest acquisitions to date in the medical device sector. The deal, structured as approximately 73 percent cash and 27 percent stock, offers Penumbra shareholders $374 per share and is expected to close in 2026, subject
Guardant Health and Merck announce global CDx collaboration using Infinity Smart liquid biopsy platform. Find out what this means for oncology drug development.
Find out how Henry Schein’s exclusive U.S. deal for CytoChip’s CLIA-waived CitoCBC could reshape point-of-care blood diagnostics.
EndoQuest wins FDA approval to complete PARADIGM Trial for its ELS system. Find out what this milestone means for robotic GI surgery innovation.
Provation launches iPro Lite for mobile anesthesia documentation. Find out how it could change billing, compliance, and risk in outpatient surgery centers.
iSono Health launches ATUSA™, the first wearable breast ultrasound. Find out how it could transform access, accuracy, and economics in breast imaging.
FDA clears PTOA risk reduction claim for Miach Orthopaedics’ BEAR Implant. Find out what this means for ACL treatment, patients, and future adoption.
VizMark’s VM1 marker receives FDA clearance for artifact-free breast imaging. Find out how this may change tumor localization in dense breast cases.
Amplifi Vascular's device earns FDA Breakthrough and CMS Category B status. Find out what this means for dialysis access innovation and payer alignment.
Find out how Strive’s acquisition of Semler Scientific strengthens its diagnostic and patient monitoring capabilities in the regulated medical device market.